Fake painkillers are circulating in the Netherlands, authorities warn after man dies
Dutch authorities are warning people against ordering prescription painkillers online after a 30-year-old man died in Amsterdam after taking counterfeit oxycodone.
The pills were bought online without a prescription, according to the Trimbos Institute, a Dutch scientific research agency.
They did not contain oxycodone – which is prescribed for patients with severe pain – but rather nitazenes, which are synthetic opioids that are much stronger than oxycodone, morphine, or fentanyl.
The drugs are so potent that only a few milligrams can cause fatal breathing problems, according to Trimbos. The effects also last longer, raising the risk of an overdose.
Related
What the EU drugs agency chief is most worried about in 2025
Police in Amsterdam are still trying to identify where the man who died got the fake oxycodone. But his death is one of several health crises tied to synthetic drugs in the Netherlands recently.
The Dutch Health and Youth Care Inspectorate (IGJ) said multiple people have received emergency medical care after taking pills that were sold online as oxycodone but turned out to contain nitazenes.
The drugs are sold online and on social media, the inspectorate said. They look like oxycodone and typically have original-looking packaging – making them 'almost indistinguishable' from the real thing, it added.
Related
From cannabis to cocaine: What are the most commonly used illicit drugs in the EU?
'This shows how dangerous it is to order prescription drugs online,' IGJ chief inspector Henk de Groot said in a statement.
'It may look real, but you have absolutely no idea what you are buying'.
The warning comes amid an uptick in the availability of nitazenes and other synthetic opioids in parts of Europe, according to the European Union Drugs Agency, which described them as an 'important emerging threat'.
Related
'Missing piece of the jigsaw': Glasgow hopes safe injection site will curb overdose deaths
Trimbos urged people to avoid buying pain medication online and said people should call for emergency help if they begin feeling unwell after taking oxycodone.
Meanwhile, IGJ said people can report websites selling prescription medicines to investigators.
'For drugs, go to your doctor and pharmacy,' de Groot said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
More than 1,200 mothers and 900 children impacted by Dutch fertility scandal
A popular Dutch fertility clinic used sperm from dozens of donors far more than the 25 permitted times for over a decade, affecting hundreds of children and mothers. One of the Netherlands' largest fertility clinics, Medisch Centrum Kinderwens (MCK), used sperm from at least 36 donors many more times than permitted between 2006 and 2017, Dutch news outlet Nos reported, affecting more than 900 mothers and 1,200 children. Dutch youth minister Vincent Karremans said it was an 'appalling' case which would understandably lead to anger and questions from those affected. 'They are now confronted with the news that their children belong to a larger kinship network than they had expected or wanted. The children appear to have more half-brothers or -sisters than thought,' he said in response to questions from Nos. 'And the donors appear to have more offspring than they themselves thought. I can imagine that this can have a major impact on each of them.' In April, Nos's current affairs programme Nieuwsuur shocked the Netherlands when it revealed that Dutch fertility clinic practices had resulted in at least 85 mass donors. A mass donor is someone who has more than 25 offspring, which was the maximum limit permitted by the country's professional association of gynaecologists until 2018, when the limit was reduced to a maximum of 12 families per donor. MCK confirmed it had 36 mass donors, and blamed previous management for ignoring the guidelines. In a statement to Nos, MCK director Wouter van Inzen blamed the number of mass donors on a donor shortage and high demand from mothers, as well as the 'desire for multiple children from the same donor within one family'. Current management took over in 2015 and ended the practice in 2017, but Mr van Inzen said the clinic decided not to approach the donors and parents involved in the issue 'in consultation with the professional group'. The Donorkind Foundation, an advocacy group, said: 'Prospective parents are nothing more than paying customers, donors are a kind of raw material and donor children nothing more than products'. Priamos, the sperm donors' association, said the clinic's actions were "irresponsible and unscrupulous". Donors were asked from 2006 whether they wanted to donate for 25 families, rather than 25 children, and their contracts allowed a certain number of children to be conceived in other countries. Priamos said while those contracts were in breach of the rules, all the donors the association spoke to thought donating to 25 families was permitted. 'We are not aware of any donor who was made aware that the rules were being violated. Donors do not need to know the rules either. They can assume that they will be treated fairly by the clinic,' the association told Nos.
Yahoo
5 hours ago
- Yahoo
Newel Health obtains EU MDR for blood pressure management platform
Amid the growing prevalence of hypertension in the EU, Italian health tech Newel Health has secured a CE mark for its Amicomed platform under the EU's Medical Device Regulation (EU MDR), enabling it to support the management of high blood pressure. Compatible with blood pressure monitors including Apple Health and Google Fit, the smartphone app-based platform captures structured blood pressure data and translates it into 'clinically meaningful' insights, Newel Health stated, and offers personalised feedback towards high blood pressure management based on real-world data. The platform's features include medication reminders to improve adherence, and personalised lifestyle and dietary recommendations based on a user's clinical profile. The capabilities are supported by Amicomed's architecture. Developed by Newel Health, the proprietary platform uses artificial intelligence (AI)-based predictive models to improve behavioural segmentation, sustain engagement, and adapt interventions based on an individual's profile. A 2023 report by GlobalData forecasts that AI platforms in healthcare will reach a valuation of $18.8bn by 2027. Newel Health CEO, Ervin Ukaj commented: "We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach.' Ukaj added that Newel intends to pursue 'scalable growth' by seeking further partnerships with public and private healthcare stakeholders. Systemic hypertension is a key risk factor for chronic disease burden, and a known precursor for cardiovascular diseases (CVDs) including atherosclerotic cardiovascular disease, with research indicating that hypertension in the EU is on the rise. A European Commission (EC) survey from 2019 found that 22% of individuals aged 15 and above reported having received a high blood pressure diagnosis from a medical professional, while a 2023 report by the World Health Organization (WHO) estimates that the number of adults with hypertension in the European region and the Americas rose from 302 million in 1990 to 427 million in 2019 – reflecting a 41% rise. All medical device manufacturers marketing products in the EU must fall in line with the dictates of the EU MDR regulation by 2028. Introduced in 2017 and coming into its 'first phase' of effect in 2021, the EU MDR is promulgated as a means to centralise competencies at the EU level. While well-intentioned, some observers have deemed the regulation's roll out a 'disaster', with concerns around a perceived lack of clarity, and the regulation's overall scope and complexity – factors that have proven particularly challenging for companies with existing device on the European market. "Newel Health obtains EU MDR for blood pressure management platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Newel Health obtains EU MDR for blood pressure management platform
Amid the growing prevalence of hypertension in the EU, Italian health tech Newel Health has secured a CE mark for its Amicomed platform under the EU's Medical Device Regulation (EU MDR), enabling it to support the management of high blood pressure. Compatible with blood pressure monitors including Apple Health and Google Fit, the smartphone app-based platform captures structured blood pressure data and translates it into 'clinically meaningful' insights, Newel Health stated, and offers personalised feedback towards high blood pressure management based on real-world data. The platform's features include medication reminders to improve adherence, and personalised lifestyle and dietary recommendations based on a user's clinical profile. The capabilities are supported by Amicomed's architecture. Developed by Newel Health, the proprietary platform uses artificial intelligence (AI)-based predictive models to improve behavioural segmentation, sustain engagement, and adapt interventions based on an individual's profile. A 2023 report by GlobalData forecasts that AI platforms in healthcare will reach a valuation of $18.8bn by 2027. Newel Health CEO, Ervin Ukaj commented: "We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach.' Ukaj added that Newel intends to pursue 'scalable growth' by seeking further partnerships with public and private healthcare stakeholders. Systemic hypertension is a key risk factor for chronic disease burden, and a known precursor for cardiovascular diseases (CVDs) including atherosclerotic cardiovascular disease, with research indicating that hypertension in the EU is on the rise. A European Commission (EC) survey from 2019 found that 22% of individuals aged 15 and above reported having received a high blood pressure diagnosis from a medical professional, while a 2023 report by the World Health Organization (WHO) estimates that the number of adults with hypertension in the European region and the Americas rose from 302 million in 1990 to 427 million in 2019 – reflecting a 41% rise. All medical device manufacturers marketing products in the EU must fall in line with the dictates of the EU MDR regulation by 2028. Introduced in 2017 and coming into its 'first phase' of effect in 2021, the EU MDR is promulgated as a means to centralise competencies at the EU level. While well-intentioned, some observers have deemed the regulation's roll out a 'disaster', with concerns around a perceived lack of clarity, and the regulation's overall scope and complexity – factors that have proven particularly challenging for companies with existing device on the European market. "Newel Health obtains EU MDR for blood pressure management platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
